Red Cell Life Span (RBC) in Chronic Kidney Disease (CKD)
Red Blood Cell (RBC) Survival in Patients with Chronic Kidney Disease (CKD) and on Dialysis
University of Otago
56 participants
Oct 1, 2009
Observational
Conditions
Summary
Anaemia associated with chronic kidney disease (CKD) is believed to be caused by erythropoietin deficiency and decreased red blood cell (RBC) survival. The toxic uremic environment and mechanical damage caused by dialysis is thought to account for the reduced red cell life span. However the clinical evidence for this is minimal. To date no accurate data on RBC survival in CKD is available. We propose to undertake a study to investigate red blood cell survival in patients with moderate CKD, on haemodialysis and on peritoneal dialysis in comparison with controls. RBC survival will be measured by means of labelling with radioactive chromium. As almost half the patients with CKD are diabetic, glycaemic control remains an important aspect of their management. Therefore RBC survival will influence the accuracy of markers of glycaemic control, like HbA1c.
Eligibility
Plain Language Summary
Simplified for easier understanding
This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This study is designed to investigate red blood cell survival in patients with moderate CKD, on haemodialysis and on peritoneal dialysis in comparison with controls. RBC survival will be measured by means of labelling with radioactive chromium, whereby a sample of RBCs of a cross-section of ages is tagged and the disappearance of radioactivity is followed over a period of 4 weeks time.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000145000